- Home
- KTF vs IMNM Comparison
KTF vs IMNM Comparison
Compare KTF & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTF
- IMNM
- Stock Information
- Founded
- KTF 1988
- IMNM 2006
- Country
- KTF United States
- IMNM United States
- Employees
- KTF N/A
- IMNM N/A
- Industry
- KTF Finance Companies
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- KTF Finance
- IMNM Health Care
- Exchange
- KTF Nasdaq
- IMNM Nasdaq
- Market Cap
- KTF 384.3M
- IMNM 747.7M
- IPO Year
- KTF N/A
- IMNM 2020
- Fundamental
- Price
- KTF $9.47
- IMNM $10.97
- Analyst Decision
- KTF
- IMNM Strong Buy
- Analyst Count
- KTF 0
- IMNM 5
- Target Price
- KTF N/A
- IMNM $28.60
- AVG Volume (30 Days)
- KTF 103.3K
- IMNM 874.7K
- Earning Date
- KTF 01-01-0001
- IMNM 11-13-2024
- Dividend Yield
- KTF 3.54%
- IMNM N/A
- EPS Growth
- KTF N/A
- IMNM N/A
- EPS
- KTF 0.39
- IMNM N/A
- Revenue
- KTF N/A
- IMNM $10,129,000.00
- Revenue This Year
- KTF N/A
- IMNM N/A
- Revenue Next Year
- KTF N/A
- IMNM N/A
- P/E Ratio
- KTF $23.10
- IMNM N/A
- Revenue Growth
- KTF N/A
- IMNM N/A
- 52 Week Low
- KTF $7.40
- IMNM $8.33
- 52 Week High
- KTF $9.12
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- KTF 21.65
- IMNM 39.61
- Support Level
- KTF $9.95
- IMNM $10.76
- Resistance Level
- KTF $10.10
- IMNM $15.13
- Average True Range (ATR)
- KTF 0.09
- IMNM 0.98
- MACD
- KTF -0.06
- IMNM -0.29
- Stochastic Oscillator
- KTF 12.50
- IMNM 4.81
About KTF DWS Municipal Income Trust
DWS Municipal Income Trust is a closed-end, diversified investment management company. The investment objective is to provide high current income exempt from federal income tax by investing in a diversified portfolio of investment-grade tax-exempt securities. Its products include ETFs, Mutual Funds, Closed-End-Funds, Money Market Funds, and others.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.